Navigation Links
SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference

DUBLIN, Calif., July 06, 2007 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that Dr. Gregory Berk, Chief Medical Officer, will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Thursday, July 12, 2007 at the Mandarin Oriental Hotel in New York City.

SuperGen's presentation at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference is scheduled to begin at 3:30 p.m. EDT. A live webcast of the presentation will be available on the Investor Relations section of the Company's Web site at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

    Contacts:

    SuperGen                                SuperGen

    Timothy L. Enns                         Mary M. Vegh

    S.V.P., Corporate Communications        Manager, Investor Relations

    & Business Development                  (925) 560-2845

    (925) 560-0100 x111
mary.vegh@supergen.com tenns@supergen.com

CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment, +1-925-560-0100, Ext. 111, , or Mary M.Vegh, Manager, Investor Relations, +1-925-560-2845, ,both of SuperGen tenns@supergen
'"/>




Page: 1 2

Related medicine technology :

1. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
2. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:10/6/2008)... Conference Call Scheduled for 9:00 AM ET Today -,...on Corporation (Nasdaq:,DNDN) announced today that...the Phase 3, randomized, double-blind, placebo-con...rcinoma Treatment, also known as D9902B),clinical ...f the,investigational active cellular immunotherap...
(Date:10/6/2008)... Procedure May Eliminate 6 Weeks of Radiation Ther...t over the Internet Wednesday, October 22, 2008...xplorehealth , HAMPTON, Va., Oct. 6 /PRNewswire/ ...e was diagnosed with breast cancer in May. Would s...w about radiation or chemotherapy?, , To view th...
(Date:10/6/2008)...ept of Other Product - Company,s Bioabsorbable Ste...ONG KONG, Oct. 6 /- Data from multipl... stent, OrbusNeich,s Genous Bio-engineered R,stent... Cardiovascular,Therapeutics symposium, TCT 2008, ...D., of the Academic Medical Center in,Amsterdam wi...
(Date:10/5/2008)...blished in New England Journal of Medicine reaffir...rofile of SPIRIVA(R),HandiHaler(R), RIDGEFIELD, C... of the,UPLIFT (Understanding Potential Long-term ... that SPIRIVA(R) HandiHaler(R) (tiotropium bromide...g function for up to 4,years as measured by FEV(1)...
Breaking Medicine Technology:Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6AARP Maryland Key Vote News Alert 21748 1AARP Maryland Key Vote News Alert 21748 2AARP Maryland Key Vote News Alert 21748 3Biopure Granted Additional 180 Day Compliance Period by NASDAQ 5972 1Biopure Granted Additional 180 Day Compliance Period by NASDAQ 5972 2XTENT Announces European Regulatory Update 2414 1XTENT Announces European Regulatory Update 2414 2XTENT Announces European Regulatory Update 2414 3JCI online early table of contents 3A June 12 2008 21746 1JCI online early table of contents 3A June 12 2008 21746 2JCI online early table of contents 3A June 12 2008 21746 3JCI online early table of contents 3A June 12 2008 21746 4JCI online early table of contents 3A June 12 2008 21746 5JCI online early table of contents 3A June 12 2008 21746 6JCI online early table of contents 3A June 12 2008 21746 7
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
...chnique to find out if metastasis from the eye can... research scientists at Washington University Scho...for the prediction of whether melanoma of the eye ...kly transform into being very lethal. The scientis...
...al age for buying cigarettes in Scotland to 18 yea...or NHS Scotland has led a team of experts //who ar...h Executive. Health Minister Andy Kerr said that s...ts do not take up the habit. "We must get a strong...
Overseas Trained Nurses To Be Allowed To Retrain For Scottish Jobs
...le can be a common feature but could be prevented.... System//, have stated that many a times the simpl... shower, for older people could turn out to be a d...eature. The study that appears in the Journal of ...
Other Medicine News:Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 2Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 3Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 4Health News:Common Falls In Bath Among Older Adults Can Be Prevented 2Health News:Common Falls In Bath Among Older Adults Can Be Prevented 3
Para 12 Plus is a hematology control for the Abbott CELL-DYN 3000, 3200, and 3500/3700. Assay values are provided for the five-part white cell differential, as well as a three-part differential on th
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions.
... 5X is a whole blood hematology control manufactur...0, and the Coulter AcT5diff instruments. The compo...differential, positioning the populations within t...he product offers 105-day closed-vial stability an...
...-Chex is a spinal and body fluid control with dist... the same manner as a patient sample, the white bl...trol is assayed for manual cell counting, the five...e two-part polymorphonuclear and mononuclear diffe...
Medicine Products: